Home / Resource Library / Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for early-stage classical Hodgkin Lymphoma: Updated results from an ongoing phase 2 study (SGN35-027 Part C)

Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for early-stage classical Hodgkin Lymphoma: Updated results from an ongoing phase 2 study (SGN35-027 Part C)

ICML 2023

Membership Organisation

Healthcare Professional

Affected by Lymphoma

Researcher or Advocate

Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for early-stage classical Hodgkin Lymphoma: Updated results from an ongoing phase 2 study (SGN35-027 Part C)